跳至主要内容
临床试验/TCTR20230720001
TCTR20230720001已完成2 期

THE SAFETY AND EFFICACY OF Cymbopogon citratus Stapf. EXTRACT IN CHRONIC KIDNEY DISEASE PATIENTS STAGE 3B; A DOUBLE BLIND RANDOMIZE CONTROL TRIA

THAI TRADITIONALMEDICALKNOWLEDGE FUND, Thailand0 个研究点目标入组 64 人开始时间: 2023年7月20日最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
64

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
35 Years 至 85 Years(—)
性别
All

入选标准

  • 1.Male or female participants aged between 35- 85 years
  • 2.Participants with stage 3B chronic kidney disease and had an eGFR between 30-44 ml / min / 173m2.

排除标准

  • 1.Participants with cancer of all types from the first stage onwards
  • 2.Participants with heart disease or heart abnormality in all cases
  • 3.Participants with liver disease, hepatitis, cirrhosis, fatty liver
  • 4.Participants with diabetic nephropathy
  • 5.Participants with chronic infection and are undergoing treatment for an infection
  • 6.Participants with alcoholism
  • 7.Participants with autoimmune disease, SLE, rheumatoid arthritis and are taking corticosteroids, immunosuppressants or immunosuppressive agents
  • 8.Participants with during of pregnant or breastfeeding
  • 9.Participants with history of lemongrass allergy
  • 10.Participants with prolonged obstruction of the urinary tract, such as enlarged prostate and kidney stones
  • 11.Participants with overactive bladder (OAB)
  • 12.Participants currently participating in another study

研究者

发起方
THAI TRADITIONALMEDICALKNOWLEDGE FUND, Thailand

相似试验